Alkermes plc (ALKS)
NASDAQ
Closed
Oct 7, 2026
Day's Range
41.1752 wk Range
27.00Overview - ALKS - Alkermes plc
Key Statistics
Valuation
Enterprise Value
7.92B
P/E (Trailing)
‪109.86‬
P/E (Forward)
‪23.08‬
PEG Ratio
‪-1.09‬
Price / Sales (TTM)
‪4.19‬
Price / Book
‪3.86‬
EV / EBITDA
‪27.79‬
Profitability
Profit Margin
‪3.96%‬
Operating Margin
‪15.49%‬
Return on Assets
‪4.20%‬
Return on Equity
‪3.85%‬
Ownership
Shares Outstanding
167.76M
Float
155.19M
Short % of Shares Outstanding
‪12.52%‬
Held by Insiders
‪1.40%‬
Held by Institutions
‪107.47%‬
Price stats
Beta
‪0.26‬
50-Day Avg
‪47.17‬
200-Day Avg
‪39.02‬
Dividends
Payout Ratio
‪0.00%‬
Analyst Consensus
19 analysts
Average price target
‪$ 56.00‬Shariah Compliance
Report Date: Feb 17, 2025
Screened by Zoya using the AAOIFI methodology.
Market Cap - ALKS - Alkermes plc
Peers - ALKS - Alkermes plc
Peer Comparison
Compared with companies in Drug Manufacturers - Specialty & Generic listed on NASDAQ.
- ALKSNASDAQAlkermes plc7.00BMarket Cap+25.77%52-week change109.87P/E (Trailing)‪3.96%‬Profit Margin
- NBIXNASDAQNeurocrine Biosciences, Inc.14.55BMarket Cap+2.62%52-week change20.93P/E (Trailing)‪20.91%‬Profit Margin
- AMRXNASDAQAmneal Pharmaceuticals, Inc.7.07BMarket Cap+48.03%52-week change42.29P/E (Trailing)‪5.04%‬Profit Margin
- LNTHNASDAQLantheus Holdings Inc.6.52BMarket Cap+47.28%52-week change23.91P/E (Trailing)‪17.69%‬Profit Margin
- KNSANASDAQKiniksa Pharmaceuticals International, plc Class A Ordinary Shares5.83BMarket Cap+49.48%52-week change76.56P/E (Trailing)‪9.59%‬Profit Margin
- DIODNASDAQDiodes Incorporated4.43BMarket Cap+44.79%52-week change51.08P/E (Trailing)‪5.26%‬Profit Margin
- INDVNASDAQIndivior Pharmaceuticals, Inc.4.21BMarket Cap+36.35%52-week change12.68P/E (Trailing)‪26.74%‬Profit Margin
Profile Summary - ALKS - Alkermes plc
About
Alkermes plc is a global biopharmaceutical company focused on developing, manufacturing, and commercializing medicines for central nervous system disorders and other serious conditions. Its current portfolio includes treatments for schizophrenia, bipolar I disorder, alcohol dependence, opioid dependence, and…
The information on this page is provided for general informational purposes only and is not investment advice.
Market data provided by Twelve Data. Shariah compliance data provided by Zoya. Charting by TradingView.
Last updated:
